Osteoarthritis Market: Competitive Strategies, Regional Analysis Forecast 2030
The global osteoarthritis market is poised to capture a CAGR of approximately 6.8% over the forecast period of
2017-2023, proclaims Market Research Future (MRFR) in a minutely analysed
research report. The market is growing persistently on account of growing
global geriatric population as it accounts for more disability among the
elderly population than any other disease. Elderly patients have been reported
to experience radiographic osteoarthritis which increases as patients age.
Rising populace of obesity is also considered to be the driving factor in the
growth of the global osteoarthritis market since obesity has also been
identified as a risk factor for osteoarthritis. Obesity reduces the
skeletal-weight-to-body-mass which results in compressive forces to joints.
Although the treatment market for
osteoarthritis is not robust, increased prevalence of the disease has resulted
in increased R&D activities which are expected to bring new treatment
options to the market. Moreover, raising awareness about the disease may induce
demand for medications and boost market growth. Low access to healthcare and
the side effects of the treatment procedures are the most significant hurdles
to the growth of the global osteoarthritis market. Stem cells treatments have
been demonstrated as a possible treatment for osteoarthritis which is expected
to provide growth opportunities to the global Osteoarthritis Market.
Competitive Landscape
The key players in the global
osteoarthritis market include Regeneron (U.S.), Novartis AG (Europe),
TissueGene Inc. (U.S.), Eli Lilly and Company. (U.S.), Pfizer Inc. (U.S.),
Abbott. (U.S.), Ampio Pharmaceuticals Inc. (U.S.), ABIOGEN PHARMA S.p.A
(Europe), and Merck Sharp & Dohme Corp. (U.S.).
Segmentation
The global osteoarthritis market has
been segmented based on type, diagnosis, treatment, and end users. By type, the
osteoarthritis disability rating market has been segmented into hip osteoarthritis, wrist
osteoarthritis, spinal osteoarthritis, and others.
By diagnosis, the osteoarthritis
therapeutics market has been segmented into imaging, joint fluid analysis,
and others. The imaging segment is sub-segmented into X-rays, magnetic
resonance imaging (MRI), and others.
By treatment, the osteoarthritis has been segmented
into medication, surgery, therapy, and others. The medication segment has been
further segmented into analgesics and non-steroidal anti-inflammatory drugs,
and others. The analgesic sub-segment has been further segmented into
acetaminophen, duloxetine, and others. The non-steroidal anti-inflammatory
drugs sub-segment has been further segmented into aspirin, ibuprofen, naproxen
sodium and naproxen, and others.
By end users, the osteoarthritis segment has been
hospitals & clinics, medical institutes, research organization, and others.
Regional Analysis
The global osteoarthritis market spans
across the regions of the Americas, Europe, Asia Pacific, and the Middle East
& Africa. The Americas hold the dominant position in the global
osteoarthritis market. A robust healthcare sector, huge osteoarthritis patient
pool, and high healthcare expenditure support the growth of the Americas market.
Europe has commanded the second
position in the global osteoarthritis market. Availability of funds for
research and development activities coupled with government support, high
healthcare expenditure and growing prevalence of osteoarthritis in the region
propels the growth of the Europe market.
Asia Pacific follows Europe in the
global osteoarthritis market. The presence of a huge patient population, rising
healthcare investments in the developing economies, and the untapped markets of
the region provide a lucrative opportunity for market expansion. Moreover,
favorable government policies aid market growth and will help Asia Pacific to
emerge as the fastest growing market for osteoarthritis.
The Middle East & Africa holds the
least share in the global osteoarthritis market. Poor economic condition and
low penetration of healthcare limit the growth of the market, especially in the
Africa region and most of the market share is held by the Middle East market.
The healthcare sector is well-developed in the Gulf countries which helps the
Middle East market progress.
Industry Updates
In August 2018, the FDA launched new
draft guidance for Osteoarthritis Treatments. The new set of rules will guide
drug and medical device manufacturers to develop treatments for
osteoarthritis.
About US:
Market Research Future (MRFR) enable customers to unravel
the complexity of various industries through Cooked Research Report (CRR),
Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed
Research (CFR), and Market Research & Consulting Services.
Contact us:
Market Research Future (part of Wantstats Research and Media
Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013
Comments
Post a Comment